Citations

Clear

2960 citation(s) found for "Kim, P".

Independent Validation of the 2010 American Joint Committee on Cancer TNM Classification for Renal Cell Carcinoma: Results From a Large, Single Institution Cohort
Kim, Simon P. , Alt, Angela L., Weight, Christopher , Costello, Brian A. , Cheville, John C. , Lohse, Christine M. , Allmer, Cristine, Leibovich, Bradley C.

Mayo Clinic

Journal of Urology | April 20, 2011 | Volume: 185 | Issue: 6 | Pages: 2035-2039

10.1016/j.juro.2011.02.059 | PMID 21496854 Get It

Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features
Huh, Yang O. , Schweighofer, Carmen D., Ketterling, Rhett P. , Knudson, Ryan A., Vega, Francisco , Kim, Ji E., Luthra, Rajyalakshmi , Keating, Michael J. , Medeiros, L. Jeffrey , Abruzzo, Lynne V. , Vega, Francisco , Ketterling, Rhett P , Medeiros, L Jeffrey

Mayo Clinic

American Journal of Clinical Pathology | April 18, 2011 | Volume: 135 | Issue: 5 | Pages: 686-696

10.1309/ajcpoefp3slx6hxj | PMID 21502423 Get It

Abstract The t(14;19)(q32;q13) involving the IGH@ and BCL3 loci is an infrequent cytogenetic abnormality detected in B-cell malignancies. We describe the clinicopathologic, cytogenetic, and molecular genetic characteristics of 14 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with t(14;19)(q32;q13). All patients (10 men and 4 women) had lymphocytosis; 10 had lymphadenopathy. Blood and bone marrow lymphocytes were predominantly small, but cytologically and immunophenotypically atypical. In all cases, t(14;19) was found in the neoplastic stem line; it was the sole abnormality in 4. Ten cases showed additional cytogenetic abnormalities, including trisomy 12 in 9 and complex karyotypes in 7. Fluorescence in situ hybridization demonstrated IGH@/BCL3 fusion gene in all cases. In all cases, the IGHV genes were unmutated, but only 7 expressed ZAP70. Seven cases preferentially used IGHV4-39. Our results indicate that t(14;19)(q32;q13) identifies a subset of CLL/SLL with distinctive clinicopathologic and genetic features. Furthermore, t(14;19) may represent an early, possibly primary, genetic event.
LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer
Permuth‐Wey, Jennifer, Tsai, Ya-Yu, Lin, Hui‐Yi , Chen, Y. Ann , Barnholtz‐Sloan, Jill S. , Birrer, Michael J. , Bloom, Gregory, Chen, Zhihua , Cunningham, Julie M. , Dagne, Getachew , Ebbert-Syfrett, Judith, Fenstermacher, David, García‐Closas, Montserrat , Gayther, Simon A. , Bosquet, Jesús González , Goode, Ellen L. , Iversen, Edwin S., Kong, William, McLaughlin, John, Menon, Usha , Monteiro, Álvaro N.A. , Narod, Steven A., Phelan, Catherine M., Qu, Xiaotao , Ramus, Susan J. , Schildkraut, Joellen M. , Song, Honglin , Stockwell, Heather, Sutphen, Rebecca , Terry, Kathryn L. , Vierkant, Robert A. , Wentzensen, Nicolas , Lancaster, Johnathan M., Cheng, Jin Q. , Sellers, Thomas A. , Kim, Donghwa , Chanock, Stephen Jacob , Cramer, Daniel W. , Fridley, Brooke L. , Ge, William H. , Gentry‐Maharaj, Aleksandra , Jim, Heather , McLaughlin, John, Pharoah, Paul D.P. , Risch, Harvey A. , Tyrer, Jonathan P. , Ramus, Susan J , Vierkant, Robert A , Menon, Usha , Monteiro, Alvaro N , Barnholtz-Sloan, Jill S , Lin, Hui-Yi , García-Closas, Montserrat , Bosquet, Jesus Gonzalez

Mayo Clinic

Cancer Research | April 12, 2011 | Volume: 71 | Issue: 11 | Pages: 3896-3903

10.1158/0008-5472.can-10-4167 | PMID 21482675 Get It

Abstract Defective microRNA (miRNA) biogenesis contributes to the development and progression of epithelial ovarian cancer (EOC). In this study, we examined the hypothesis that single nucleotide polymorphisms (SNP) in miRNA biogenesis genes may influence EOC risk. In an initial investigation, 318 SNPs in 18 genes were evaluated among 1,815 EOC cases and 1,900 controls, followed up by a replicative joint meta-analysis of data from an additional 2,172 cases and 3,052 controls. Of 23 SNPs from 9 genes associated with risk (empirical P < 0.05) in the initial investigation, the meta-analysis replicated 6 SNPs from the DROSHA, FMR1, LIN28, and LIN28B genes, including rs12194974 (G>A), an SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR = 0.90, 95% CI: 0.82–0.98; P = 0.015) which has been recently implicated in age of menarche and other phenotypes. Consistent with reports that LIN28B overexpression in EOC contributes to tumorigenesis by repressing tumor suppressor let-7 expression, we provide data from luciferase reporter assays and quantitative RT-PCR to suggest that the inverse association among rs12194974 A allele carriers may be because of reduced LIN28B expression. Our findings suggest that variants in LIN28B and possibly other miRNA biogenesis genes may influence EOC susceptibility. Cancer Res; 71(11); 3896–903. ©2011 AACR.
Abstract 25: PD 0332991, a selective CDK 4/6 inhibitor, preferentially inhibits growth of ovarian cancer cells with high Rb and low p16 (CDKN2A) expression
Kolarova, Teodora , Winterhoff, Boris , Manivong, Kanthinh, Chalukya, Meenal, Kalli, Kim, Hartmann, Lynn C. , Cliby, William A. , Slamon, Dennis J. , Konecny, Gottfried E. , Qi, Jingwei , Kalli, Kimberly R.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 25-25

10.1158/1538-7445.am10-25 Get It

Abstract Background: Cell cycle dysregulation is a common molecular finding in ovarian cancer and the cyclin-D kinases (CDK) represent an attractive target in this pathway. PD 0332991 (Pfizer Inc.) is an orally active potent and highly selective inhibitor of CDK 4 and CDK6 kinases with the ability to block pRb phosphorylation at serine 780 and 795 in the low nanomolar range. To identify predictors of response to PD 0332991, we determined the in vitro sensitivity to PD 0332991 in a large panel of molecularly characterized ovarian cancer cell lines, and then used baseline expression profiles and Western blot analyses to identify biomarkers associated with response to PD 0332991. These biomarkers were then validated in a large cohort of 324 ovarian cancer patients by immunohistochemistry. Methods: 40 human ovarian cancer cell lines were treated with PD 0332991 using two-fold dilutions over 12 concentrations. Dose response curves were generated using a cell count assay to calculate the IC50 across the panel. These data were then analyzed against baseline gene expression data to identify genes associated with sensitivity to PD 0332991. Western blot analysis was performed to validate these markers and to study the effects of PD 0332991 on pRb phosphorylation. Cell cycle analysis was performed using flow-cytometry. Combination studies were performed to analyze the interaction between PD 0332991 and paclitaxel or carboplatin chemotherapy. Tissue microarrays were constructed from 324 ovarian cancer patients and IHC was performed for p16 and Rb expression. Long-term clinical follow up was available for all patients. Results: Concentration-dependent anti-proliferative effects of PD 0332991were seen in all ovarian cancer cell lines tested, but varied significantly between individual cell lines with up to a 3 log-fold difference in the IC50s (IC50 range: 0.02 to >20 μmol/L). Cell lines with high Rb expression and low p16 expression by gene expression array and Western blot analyses were most sensitive to inhibition by PD 0332991. Cell lines treated with PD 0332991 showed clear G0/G1 arrest and a decrease in S-phase fraction in sensitive but not in resistant cell lines. In addition, Western blot showed that pRb phosphorylation is blocked in a concentration and time dependent manner. IHC for Rb and p16 allows the identification of ovarian cancer patients most likely to benefit from CDK4/6 inhibition. Outcome analyses are ongoing. Conclusion: PD 0332991 shows promising biologic activity in ovarian cancer cells. Assessment of Rb and p16 expression may help select patients who benefit from therapeutic strategies targeting CDK4/6 in ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 25.
Abstract 2005: The evolutionarily conserved gene expression signatures SPARC and SPP1 are genetic determinants of progression from Barrett's esophagus to esophageal adenocarcinoma
Kim, Soo Mi , Kim, Sangbae , Park, Eun Sung , Park, Yun‐Yong , Buttar, Navtej , Wang, Kenneth K. , Lee, Jeffrey H. , Wu, Xifeng , Izzo, Julie, Lee, Ju‐Seog , Choi, Y. , Bhutani, Manoop S. , Ajani, Jaffer A.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 2005-2005

10.1158/1538-7445.am10-2005 Get It

Abstract Esophageal adenocarcinoma (EAC) is thought to arise from the metaplastic condition known as Barrett's esophagus (BE), which is caused by chronic inflammation due to gastroesophageal reflux disease. Since the molecular mechanisms underlying the pathogenesis of EAC are unknown, understanding EAC development mechanisms and their regulation is crucial for the treatment of EAC. Comparative genomic studies of evolutionarily similar and dissimilar species have been suggested as a means of studying the evolutionary biology in the species. Thus, we performed a cross-species comparison of gene expression patterns in human and rat tissues, uncovering the evolutionarily conserved gene expression patterns during EAC progression across both species. Using a non-carcinogenic rat model that progresses from normal esophagus to BE to EAC, we were able to identify the biological mechanisms of EAC development. We analyzed gene expression data from rat specimens (15 NE, 18 BE, and 30 EAC) as well as from human tissues (28NE, 72BE, and 75EAC). Using the presence of orthologous genes in both microarray platforms and various statistical tests, we uncovered a number of genes whose expression patterns were well conserved during progression from NE to BE in humans and rats. The expression of 869 genes was commonly altered when NE progressed to BE in both humans and rats (P<0.005). One of the most significantly conserved signaling pathways during the progression from NE to BE was IL-6-mediated E2F transcription factor1 (E2F1). The increased E2F1 induced activation of CCNA2, CCNB2, CCND1, CCNE 1 and 2, CDC 2 and 6, CASP3, CASP6, CASP8, CASP9, and Rad 51, which are important genes for the regulation of cell cycle, apoptosis, and DNA repair. These up-regulated genes may consequently cause abnormal cell cycle regulation and induce dysplasia and metaplasia of normal esophagus tissue during NE to BE progression. During BE to EAC progression in both species, 541 gene expressions were altered (P<0.005). An increased TGF-β/RAS/SPI1 signaling pathway significantly increased the expression of SPARC and SPP1 during progression from BE to EAC. Increased SPP1 and SPARC activated MMP9, CCL2, CCL4, COL1A1, COL3A1, and SNAL1, which mostly function in invasion, cell adhesion, and migration. Intriguingly, SPP1 and SPARC already had been discovered in our previous study (Kim et al.,) as markers of poor prognosis for EAC patients, strongly indicating that SPP1 and SPARC are also genetic determinants for progression to EAC. In conclusion, systems-level characterization of gene expression data from humans and a rodent model shows evolutionarily conserved genes and pathways during EAC progression, and these genes and pathways could become reliable biomarkers for early detection, or therapeutic targets for the treatment of EAC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2005.
Evaluation of Scatter Reduction Effect of the Aft-Multiple-Slit (AMS) System Using MC Simulation
Suh, Tae Suk , Jang, Doh-Yun, Jang, H. , Chang, Jina , Kim, Siyong

Mayo Clinic

The Journal of the Korean Society for Therapeutic Radiology and Oncology | February 1, 2011 | Volume: 28 | Issue: 4 | Pages: 224

10.3857/jkstro.2010.28.4.224 Get It

In utero cell transfer between porcine littermates
McConico, Andrea L., Butters, Kim A., Lien, Karen, Wu, Xiaosheng , Platt, Jeffrey L. , Ogle, Brenda M. , Knudsen, Bruce E.

Mayo Clinic

Reproduction, Fertility and Development | January 4, 2011 | Volume: 23 | Issue: 2 | Pages: 297-302

10.1071/rd10165 | PMID 21211462 Get It

Trafficking of cells between mother and fetus during the course of normal pregnancy is well documented. Similarly, cells are known to travel between twins that share either a placenta (i.e. monozygotic) or associated chorion (i.e. monochorionic). Transferred cells are thought to be channelled via the vessels of the placenta or vascular connections established via the chorion and the long-term presence of these cells (i.e. microchimerism) can have important consequences for immune system function and reparative capacity of the host. Whether cells can be transferred between twins with separate placentas and separate chorions (i.e. no vascular connections between placentas) has not been investigated nor have the biological consequences of such a transfer. In the present study, we tested the possibility of this type of cell transfer by injecting human cord blood-derived cells into a portion of the littermates of swine and probing for human cells in the blood and tissues of unmanipulated littermates. Human cells were detected in the blood of 78% of unmanipulated littermates. Human cells were also detected in various tissues of the unmanipulated littermates, including kidney (56%), spleen (33%), thymus (11%) and heart (22%). Human cells were maintained in the blood until the piglets were sacrificed (8 months after birth), suggesting the establishment of long-term microchimerism. Our findings show that the transfer of cells between fetuses with separate placentas and separate chorions is significant and thus such twins may be subject to the same consequences of microchimerism as monozygotic or monochorionic counterparts.
Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.
Rugo, HS, Roche, Hoffmann-La, Thomas, E, Chung, Heeyoung , Lerzo, Guillermo, Volles, LA, Poulart, Valerie, Perez, Edith A. , Blackwell, Kim T.

Mayo Clinic

Cancer Research | December 30, 2010 | Volume: 69 | Issue: 2_Supplement | Pages: 3057

10.1158/0008-5472.sabcs-3057 Get It

Abstract Abstract #3057 Introduction: Patients (pts) with ER/PR/HER2 negative advanced breast cancer (triple negative, TN, basal-like) have limited treatment options and a poor prognosis. Ixabepilone (ixa), the first in a new class of antineoplastic agents, showed clinical benefit in combination with capecitabine (C) in 2 large clinical trials in metastatic breast cancer (MBC) pts either resistant to (study 046; JCO, 2007) or pretreated with anthracycline (A) and taxanes (T) (study 048). In 048, ixa + C, compared to C alone, demonstrated significant increases in PFS (HR 0.79 [0.69-0.90]) and ORR (43 vs. 29%). A trend towards increased OS was seen in both 048 (HR 0.90 [0.78-1.03]) and 046 (HR 0.90 [0.77-1.05]), which did not reach statistical significance. Here we present a pooled analysis of efficacy endpoints (ORR, PFS and OS) in pts with TN disease from these 2 phase III studies.
 Methods: 1973 pts with MBC previously treated with A and T were randomized in 2 phase III trials (046 and 048) to receive either ixa (40 mg/m2 IV over 3h Q3w) + C (1000 mg/m2 PO BID x14d Q3w) or C alone (1250 mg/m2 PO BID x14d Q3w). Due to the similarity of the study populations, individual pt data from both studies was pooled to better evaluate treatment effect within pre-planned patient subgroups.
 Results: 443 pts had TN disease in the two studies combined. ORR and PFS were superior in pts receiving combination therapy compared to those on C alone with a trend towards improved survival that did not reach statistical significance.
 
 Conclusions: Ixa + C is the first combination to show statistically significant PFS benefit in pts with advanced TN breast cancer from a pooled analysis of 2 phase III trials. Clinical benefit was consistently seen pts with TN disease in the individual studies as well. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3057.
Summary of the Recommendations on Sexual Dysfunctions in Men
Montorsi, Francesco , Adaikan, Ganesan, Becher, Edgardo, Khoury, Saad, Lue, Tom F. , Sharlip, Ira D., Althof, Stanley E., Andersson, Karl-Eric, Brock, Gerald, Broderick, Gregory A. , Buvat, Jacques, Dean, John, Donatucci, Craig F., Eardley, Ian , Fugl-Meyer, Kerstin , Hackett, Geoff , Hatzichristou, Dimitris, Hellstrom, Wayne J.G. , Incrocci, Luca , Jackson, Graham, Levine, Laurence A. , Lewis, Ronald W., McCabe, Marita P. , McMahon, Chris G., Montague, Drogo K. , Montorsi, Piero, Mulhall, John P. , Pfaus, Jim, Porst, Hartmut, Ralph, David , Rosen, Raymond C., Sadeghi‐Nejad, Hossein , Shabsigh, Ridwan, Vardi, Yoram, Wallen, Kim , Wasserman, Marlene, Larcher, Alessandro , Giuliano, François , Burnett, Arthur L. “Bud” , Buvat, Jacques, Goldstein, Irwin , Kadıoğlu, Ateş , Maggi, Mario , Rowland, David L. , Stief, Christian G.

Mayo Clinic

The Journal of Sexual Medicine | October 29, 2010 | Volume: 7 | Issue: 11 | Pages: 3572-3588

10.1111/j.1743-6109.2010.02062.x | PMID 21040491 Get It

ABSTRACT Introduction Sexual health is an integral part of overall health. Sexual dysfunction can have a major impact on quality of life and psychosocial and emotional well-being. Aim To provide evidence-based, expert-opinion consensus guidelines for clinical management of sexual dysfunction in men. Methods An international consultation collaborating with major urologic and sexual medicine societies convened in Paris, July 2009. More than 190 multidisciplinary experts from 33 countries were assembled into 25 consultation committees. Committee members established scope and objectives for each chapter. Following an exhaustive review of available data and publications, committees developed evidence-based guidelines in each area. Main Outcome Measures New algorithms and guidelines for assessment and treatment of sexual dysfunctions were developed based on work of previous consultations and evidence from scientific literature published from 2003 to 2009. The Oxford system of evidence-based review was systematically applied. Expert opinion was based on systematic grading of medical literature, and cultural and ethical considerations. Results Algorithms, recommendations, and guidelines for sexual dysfunction in men are presented. These guidelines were developed in an evidence-based, patient-centered, multidisciplinary manner. It was felt that all sexual dysfunctions should be evaluated and managed following a uniform strategy, thus the International Consultation of Sexual Medicine (ICSM-5) developed a stepwise diagnostic and treatment algorithm for sexual dysfunction. The main goal of ICSM-5 is to unmask the underlying etiology and/or indicate appropriate treatment options according to men’s and women’s individual needs (patient-centered medicine) using the best available data from population-based research (evidence-based medicine). Specific evaluation, treatment guidelines, and algorithms were developed for every sexual dysfunction in men, including erectile dysfunction; disorders of libido, orgasm, and ejaculation; Peyronie’s disease; and priapism. Conclusions Sexual dysfunction in men represents a group of common medical conditions that need to be managed from a multidisciplinary perspective.
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Liao, Zhixiang , Locascio, Joseph J. , Lesniak, Kristen A., Roderick, Sarah S., Watt, Marla L., Eklund, Aron C. , Zhang‐James, Yanli , Kim, Peter D., Hauser, Michael A. , Grünblatt, Edna , Moran, Linda, Mandel, Silvia, Riederer, Peter , Miller, Renee M. , Federoff, Howard J. , Papapetropoulos, Spyridon , Youdim, Moussa B. H. , Cantuti‐Castelvetri, Ippolita, Young, Anne B., Vance, Jeffery M. , Hedreen, John C. , Beach, Thomas G. , Graeber, Manuel B., Middleton, Frank A. , Rochet, Jean‐Christophe , Scherzer, Clemens R. , Papapetropoulos, Spyros , Zheng, Bin , Wüllner, Ullrich , Davis, Richard L. , Adler, Charles H.

Mayo Clinic

Science Translational Medicine | October 6, 2010 | Volume: 2 | Issue: 52 | Pages: No page available

10.1126/scitranslmed.3001059 | PMID 20926834 Get It

Abnormal expression of genes for energy regulation in Parkinson’s disease patients identifies a master regulator as a possible therapeutic target for early intervention.